Document Detail


Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.
MedLine Citation:
PMID:  21554204     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Glypican-3 (GPC3) is a developmentally-regulated oncofetal protein that has been established as a clinically-relevant biomarker for early hepatocellular carcinoma (HCC). It is one of the first transcripts to appear during malignant hepatocyte transformation, and is expressed at the protein level in approximately half of high-grade dysplastic macronodules in cirrhotic liver. Several studies show it is expressed in most (75 to 100%) of HCCs confirmed by histopathology. The protein is anchored to the hepatocyte membrane by a glycosyl-phosphatidylinositol (GPI) anchor and shows consistent membrane immunostaining pattern, making it a viable target for immunotherapeutic approaches. Targeting GPC3 for therapeutic intervention is a promising approach for the clinical management of HCC and selected other tumors that express the marker.
Authors:
Mark Allegretta; Jorge Filmus
Related Documents :
23747354 - Over-expression of the mirna cluster at chromosome 14q32 in the alcoholic brain correla...
7670654 - Selective c-jun expression in ca1 neurons of the gerbil hippocampus during and after ac...
10395074 - Negative regulation of glucocorticoid-dependent induction of c-fos by ras in intestinal...
1761754 - Specific temporal and spatial distribution of jun, fos, and krox-24 proteins in spinal ...
24940614 - Proteomic analysis of mouse testis reveals perfluorooctanoic acid induced reproductive ...
11587354 - Quantitative determination of gene expression in human lymphocytes assessed by reverse ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Anti-cancer agents in medicinal chemistry     Volume:  11     ISSN:  1875-5992     ISO Abbreviation:  Anticancer Agents Med Chem     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-16     Completed Date:  2011-10-04     Revised Date:  2013-12-12    
Medline Journal Info:
Nlm Unique ID:  101265649     Medline TA:  Anticancer Agents Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  543-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / chemistry
Cancer Vaccines
Carcinoma, Hepatocellular / diagnosis,  metabolism*,  therapy*
Glypicans / chemistry,  metabolism*
Humans
Immunotherapy
Liver Neoplasms / diagnosis,  metabolism*,  therapy*
Tumor Markers, Biological / metabolism*
Grant Support
ID/Acronym/Agency:
62815-3//Canadian Institutes of Health Research
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Cancer Vaccines; 0/Glypicans; 0/Tumor Markers, Biological
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  microRNA Involvement in Hepatocellular Carcinoma.
Next Document:  Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Ra...